AHA Comments to DEA on 2019 Controlled Substances Quotas

AHA comments on the Drug Enforcement Administration’s (DEA) notice of proposed rulemaking on aggregate production quotas for Schedule I and II controlled substances.

Key Resources

Related Resources

Letter/Comment
AHA Comments on HHS RFI on MAHA Initiative
Public
Letter/Comment
AHA Comments on FTC Anticompetitive Deregulations RFI
Public
Letter/Comment
AHA Comments on DOJ Anticompetitive Deregulations RFI
Public
Advisory
Trump Administration Issues Additional Deregulation Orders and Notices
Member
Advisory
Guidance for Hospitals on HHS’ Rescission of the ‘Richardson Waiver’ Affecting Public Comment
Member
Advisory
Member Advisory: Trump Administration Issues Executive Orders
Member